This study investigates the effects of an investigational gene therapy in adults with moderate Parkinson's disease. The purpose is to evaluate the safety and effectiveness of the therapy, which is delivered through a surgical infusion into the brain. Participants will be in the study for up to 5 years, with regular follow-up visits every 3 to 6 months.

Participants will be randomly assigned to receive the gene therapy or undergo a similar procedure without the therapy. This is a double-blind study, meaning neither the participants nor the study doctors will know who receives the therapy until the study ends. This approach helps compare outcomes between those who receive the therapy and those who do not.

• Who can participate: Adults aged 45 to 75 years with a diagnosis of Parkinson's disease for 4 to 10 years may participate. Key eligibility includes stable medication use and symptoms like slowness of movement with rigidity or tremor.
• Study details: Participants will undergo surgery and have follow-up visits every 3 to 6 months for 5 years. The study uses a double-blind design to compare the investigational therapy with a control procedure.
• Study timelines: The study will last up to 5 years.

To learn more about the study and to see if you are eligible to participate, visit https://mytomorro.ws/pd-mjff.